Overview and Highlights
November 2025 continued the year’s broader trend toward "Ecosystem Sovereignty" in precision medicine. Consistent with activity seen in previous quarters, industry leaders focused on acquiring diagnostic capabilities and delivery mechanisms alongside therapeutic assets. The strategy remains centered on vertical integration: connecting the diagnostic test that identifies the patient, the data platform that stratifies risk, and the specialized therapeutic that treats the specific genetic driver.
1. Strategic M&A and Consolidations
Abbott to Acquire Exact Sciences for $21 Billion November 20, 2025 Expanding its oncology portfolio, Abbott announced a definitive agreement to acquire Exact Sciences. By securing the Cologuard® and Oncotype DX® franchises, Abbott integrates established screening capabilities into its global diagnostic distribution network. This deal reflects the ongoing move from general testing toward specialized verticals in non-invasive cancer screening and precision monitoring, creating a more comprehensive system for oncology care.
Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion November 17, 2025 J&J entered into a definitive agreement to acquire Halda Therapeutics and its proprietary RIPTAC™ (Regulated Induced Proximity Targeting Chimera) platform. This technology represents an emerging class of precision oncology treatments designed to induce cancer cell death by disabling survival proteins. The lead candidate, HLD-0915, targets metastatic castration-resistant prostate cancer, offering a potential option for patients who have developed resistance to standard hormonal therapies.
Merck & Co. to Acquire Cidara Therapeutics for $9.2 Billion November 14, 2025 Merck & Co. announced the acquisition of Cidara Therapeutics to secure its drug-Fc conjugate (DFC) platform. The deal centers on CD388, a late-stage candidate for long-acting influenza prevention. By acquiring the DFC technology, Merck is investing in a "biologic-like" delivery system for small molecules and peptides, aiming to create a durable antiviral presence that complements its broader respiratory portfolio.
Pfizer Completes Acquisition of Metsera November 13, 2025 Pfizer finalized its acquisition of Metsera, providing the company with a foothold in the "precision metabolic" space. The deal adds a pipeline of next-generation, long-acting GLP-1 and nutrient-stimulated hormone (NuSH) peptides. This acquisition serves as a strategic expansion to address specific patient sub-segments with tailored, biomarker-driven metabolic agents.
2. Strategic Partnerships & Licensing
Eli Lilly & ABL Bio Ink $2.6B Bispecific Antibody Pact November 2025 Eli Lilly invested to secure access to ABL Bio’s "Grabody-B" platform. This technology focuses on crossing the blood-brain barrier (BBB) using bispecific antibodies, addressing a key challenge in precision neurology. The agreement reflects the industry's continued interest in "shuttle" technologies capable of delivering large-molecule precision medicines directly to CNS targets.
Roche Taps Manifold Bio in $2B CNS Deal November 2025 Roche partnered with Manifold Bio to utilize their protein engineering platform for central nervous system (CNS) diseases. Similar to the Lilly agreement, this partnership focuses on "brain shuttles"—specialized carriers designed to transport therapeutics across the BBB. The milestone structure highlights the value placed on delivery technologies intended to unlock the brain for precision treatment.
3. Public Markets & IPOs
Evommune Prices $150 Million IPO November 5, 2025 In a selective market environment, Evommune successfully priced its Initial Public Offering, raising $150 million to advance its pipeline of precision immunology therapies. The company’s "tissue-specific" approach aims to treat chronic inflammatory diseases while minimizing the systemic effects often associated with broad immunosuppressants. The listing indicates that public market investors remain interested in companies with differentiated mechanisms of action.
Invizyne Technologies IPO ($15 Million) November 14, 2025 Invizyne Technologies (Nasdaq: IZTC) completed its IPO mid-month. The company focuses on cell-free biomanufacturing, an enabling technology for producing complex biomarkers and precision therapeutics that are difficult to synthesize in traditional cell cultures. The listing highlights the role of the "biomanufacturing layer" within the precision medicine stack.
